Ligand and SQ Innovation enter into worldwide Captisol® license and supply agreements
Ligand and SQ Innovation announced the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand’s Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure. July 08, 2019